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The human nuclear and mitochondrial genomes co-exist within each cell. While the
mitochondrial genome encodes for a limited number of proteins, transfer RNAs, and
ribosomal RNAs, the vast majority of mitochondrial proteins are encoded in the nuclear
genome. Of the multitude of mitochondrial disorders known to date, only a ﬁfth are
maternally inherited. The recent characterization of the mitochondrial proteome therefore
serves as an important step toward delineating the nosology of a large spectrum of
phenotypically heterogeneous diseases. Following the identiﬁcation of the ﬁrst nuclear
gene defect to underlie a mitochondrial disorder, a plenitude of genetic variants that
provoke mitochondrial pathophysiology have been molecularly elucidated and classiﬁed
into six categories that impact: (1) oxidative phosphorylation (subunits and assembly
factors); (2) mitochondrial DNA maintenance and expression; (3) mitochondrial protein
import and assembly; (4) mitochondrial quality control (chaperones and proteases); (5) iron–
sulfur cluster homeostasis; and (6) mitochondrial dynamics (ﬁssion and fusion). Here, we
propose that an additional class of genetic variant be included in the classiﬁcation schema
to acknowledge the role of genetic defects in phospholipid biosynthesis, remodeling,
and metabolism in mitochondrial pathophysiology. This seventh class includes a small
but notable group of nuclear-encoded proteins whose dysfunction impacts normal mito-
chondrial phospholipid metabolism. The resulting human disorders present with a diverse
array of pathologic consequences that reﬂect the variety of functions that phospholipids
have in mitochondria and highlight the important role of proper membrane homeostasis in
mitochondrial biology.
Keywords: mitochondrial disease, phospholipid metabolism, cardiolipin, Barth syndrome, MEGDEL, DCMA,
Sengers syndrome, hereditary spastic paraplegia
MITOCHONDRIA AND DISEASE
Themitochondrion is the primary generator of adenosine triphos-
phate (ATP) in eukaryotes. In addition to oxidative phospho-
rylation (OXPHOS), the mitochondrion is involved in a wide
range of essential cellular processes. The organelle is the home
for the tricarboxylic acid cycle, fatty acid beta-oxidation, iron–
sulfur cluster biogenesis, a portion of the urea cycle, and steps
in the porphyrin and pyrimidine biosynthetic pathways. More-
over, mitochondria have important roles in Ca2+ buffering and
thus, Ca2+ signaling, are a major producer (a consequence
of OXPHOS) and scavenger of reactive oxygen species (ROS),
and are intimately involved in programmed cell death (Kroemer
et al., 1995; Green and Kroemer, 2004). Finally, the mitochon-
drion directly contributes to cellular phospholipid metabolism by
hosting machinery that can produce at least four distinct phos-
pholipids: phosphatidic acid (PA), phosphatidylglycerol (PG),
cardiolipin (CL), and phosphatidylethanolamine (PE). Given the
myriad of roles the mitochondrion plays in maintaining cellu-
lar homeostasis, it is no surprise that defects in mitochondrial
function lead to a broad spectrum of diseases (Wong, 2007).
Mitochondrial disorders, ﬁrst recognized in Luft et al. (1962),
are the most common source of inborn errors of metabolism
(Naviaux, 2004; Schaefer et al., 2008; Foundation, 2014). Primary
mitochondrial disorders can be caused by mutation of genes
encoded by either mitochondrial (mt)DNA or nuclear (n)DNA
(but whose protein product resides in the mitochondrion). Thus,
while the discovery of pathogenic mtDNA mutations in the
1980s greatly facilitated understanding of maternally-inherited
OXPHOSdisease (Holt et al.,1988;Wallace et al.,1988), the clinical
and genetic heterogeneity of mitochondrial disease still com-
plicates efforts to diagnose, manage, and treat affected patients
(Wong, 2007; Calvo and Mootha, 2010; DaRe et al., 2013).
Human mtDNA encodes 13 OXPHOS subunits, 22 transfer
RNAs, and two ribosomal RNAs (Anderson et al., 1981). In con-
trast, 99% of the mitochondrial proteome, which consists of over
1000 proteins (Mootha et al., 2003; Taylor et al., 2003; Zahedi
et al., 2006; Johnson et al., 2007; Pagliarini et al., 2008; Calvo and
Mootha, 2010; Calvo et al., 2012; Rhee et al., 2013; Hung et al.,
2014), is encoded by the nuclear genome. Thus, not surpris-
ingly, disorders that are caused by pathogenic mtDNA mutations
[identiﬁed in 30 of the 37 mtDNA-encoded proteins (Ye et al.,
2014b)] only comprise a ﬁfth of the knownmitochondrial diseases
(Dimauro and Davidzon, 2005).
Mitochondrial dysfunction is not only deﬁned by speciﬁc
defects in mtDNA or in OXPHOS-associated processes. Muta-
tions in enzymes involved in any number of the mitochondrion’s
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essential functions can lead tomitochondrial disease. Genetic vari-
ants that drive mitochondrial pathophysiology have been broadly
classiﬁed into six categories: (1) OXPHOS-related (subunits and
assembly factors; Ugalde et al., 2009); (2) mtDNA maintenance
and expression (Jacobs and Turnbull, 2005); (3) mitochondrial
biogenesis (Perez-Martinez et al., 2008); (4) mitochondrial qual-
ity control (chaperones and proteases; Koppen and Langer, 2007);
(5) iron–sulfur cluster homeostasis (Lill et al., 2012); and (6)mito-
chondrial dynamics (ﬁssion and fusion; Chen and Chan, 2009).
These categories are delineated by the pathways in which the
impacted proteins partake but do not predict in any way known,
the clinical presentation caused by any given genetic mutation.
Here, we propose that an additional class of genetic variants be
included in the classiﬁcation schema to acknowledge the role of
defects in mitochondrial phospholipid metabolism as a cause of
mitochondrial disease. This seventh class will encompass a small
but notable group of Mendelian-inherited disorders that speciﬁ-
cally impact normal mitochondrial phospholipid metabolism and
thus highlight the important role of proper membrane homeosta-
sis in mitochondrial physiology. PA, PG, CL, and PE have parts, if
not all, of their biosynthetic pathways localized to the mitochon-
drion. Combinedwith the essential import of extra-mitochondrial
phosphatidylcholine, phosphatidylserine and phosphatidylinosi-
tol, the mitochondrion requires and maintains a highly articulated
lipid trafﬁcking network. Therefore, it is no surprise that dis-
ruption of mitochondrial phospholipid metabolism can lead to
mitochondrial dysfunction.
While the mitochondrion hosts a major PE biosynthetic path-
way, to date, an inherited disease directly impinging on mito-
chondrial PE metabolism has not been demonstrated. As such,
the biology of this important phospholipid will not be covered
here. Instead, this review will only focus on those phospho-
lipids which are impacted by mutations in genes encoded by the
nuclear genome with deﬁned or emerging roles in mitochondrial
phospholipid metabolism.
CARDIOLIPIN METABOLISM
MITOCHONDRIAL MEMBRANES AND ASYMMETRY
Each mitochondrion has two highly specialized membranes, the
outer mitochondrial membrane (OMM) and inner mitochon-
drial membrane (IMM), delineating two aqueous compartments,
a dense internal matrix and an intermembrane space (IMS). Char-
acteristic to mitochondrial membranes is a low phospholipid to
protein ratio relative to other organelle membranes, high PC
and PE content, cumulatively accounting for up to 80% of total
lipid phosphorous, low amounts of sterols and sphingolipids, and
enrichment of a unique phospholipid, CL (Horvath and Daum,
2013).
Commonly known as the signature phospholipid of mito-
chondria, CL is a phospholipid dimer that consists of a pair of
PAs, each with two fatty acyl chains, bridged by a central glyc-
erol moiety (Lecocq and Ballou, 1964; Schlame et al., 2000). The
presence of four acyl chains per molecule provides the opportu-
nity for an incredible diversity of CL molecular forms while the
two phosphate groups confer upon the lipid a net –1 charge at
physiological pH (Haines and Dencher, 2002). CL, like PE and
PA, is a non-bilayer forming phospholipid; these lipids have much
smaller hydrophilic head group diameters than their hydrophobic
acyl chains, making them cone-shaped. Non-bilayer lipids partic-
ipate in membrane fusion events (Verkleij et al., 1984), facilitate
membrane bending (Gruner, 1985), and can impart order to sur-
rounding lipids (Zeczycki et al., 2014). This distinguishes them
from bilayer-forming lipids that have head groups and acyl chains
that are of similar diameter.
Each mitochondrial membrane has a distinct protein popula-
tion and phospholipid composition (Colbeau et al., 1971; Zinser
et al., 1991; Zinser and Daum, 1995; Daum and Vance, 1997;
Mootha et al., 2003; Taylor et al., 2003; Zahedi et al., 2006; John-
son et al., 2007; Pagliarini et al., 2008; Gebert et al., 2009; Rhee
et al., 2013; Hung et al., 2014). In fact, the protein to phospho-
lipid ratio differs signiﬁcantly between the IMM and OMM, with
the IMM being signiﬁcantly more proteinaceous (Sperka-Gottlieb
et al., 1988; Ardail et al., 1990; Simbeni et al., 1991).When puriﬁed,
OMMand IMMvesicles havedifferent shapes, structures, and lipid
compositions (Hovius et al., 1990; Gebert et al., 2009). Notably,
the OMM has relatively less CL than the IMM (Daum and Vance,
1997; deKroon et al., 1997). Evenwithin amembrane bilayer, there
is asymmetry in the lipid composition between the two leaﬂets
(Krebs et al., 1979; Harb et al., 1981; Cheneval et al., 1985; Sperka-
Gottlieb et al., 1988; Hovius et al., 1993; Gallet et al., 1997). For
instance, most of the associated PE and all of the low amounts
of CL are on the cytoplasmic-facing side of OMM (Hovius et al.,
1993).
The high protein to phospholipid ratio in the IMM reﬂects
the sheer magnitude of essential processes that occur in its con-
text. Embedded in the IMM is the OXPHOS system, three distinct
translocation machineries (TIM22, TIM23, and OXA1), carrier
proteins thatmediate the ﬂux of metabolites across the IMM,qual-
ity control proteases, and phospholipid metabolizing enzymes. In
spite of this protein density, the IMM is an intact diffusion bar-
rier that enforces the proton gradient generated by the electron
transport chain. The stored power of the electrochemical gra-
dient across the IMM is central to mitochondrial biology. Not
only is it used as the source of energy for ATP production and
harnessed to drive numerous transport processes, but in fact,
the electrochemical gradient is required for mitochondrial bio-
genesis itself (Chacinska et al., 2009). Therefore, maintaining a
proper lipid composition is likely not only required to support
the functionality of the numerous proteins and protein complexes
embedded in the IMM but also to maintain its crucial barrier
function.
PA POOLS POTENTIALLY USED FOR CL PRODUCTION
Cardiolipin biosynthesis begins with PA, a common substrate in
triacylglycerol and glycerolipid metabolism. Reﬂecting this central
role, PA can be made in a multitude of ways. Worth mentioning
from the outset is that the source of PA used for CL biosynthesis
has yet to be experimentally established; given the apparent redun-
dancy, we anticipate that more than one PA-producing pathway
will be at play.
De novo biosynthesis of PA is catalyzed by glycerophosphate
acyltransferases (GPATs) that are localized to the mitochondrial
OMM (GPAT1/2; Yet et al., 1993; Lewin et al., 2004; Wang et al.,
2007) or ER (GPAT3/4; Chen et al., 2008; Nagle et al., 2008).
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GPATs transfer acyl groups from acyl-CoA donors to the sn-1 posi-
tion of glycerol-3-phosphate generating lyso-PA (LPA). Whether
and how the mitochondrial and ER GPAT isoforms contribute to
mitochondrial phospholipid metabolism is currently unresolved.
The LPA that is generated on either the OMM or within the
mitochondria-associated membrane (MAM, Vance, 1990; Gaigg
et al., 1995) subcompartment of the ER can be acylated by LPA
acyltransferases (LPAATs). In mammals, there are four LPAAT
isoforms that differ in their tissue distribution and acyl-CoA
speciﬁcities (some LPAATs can additionally acylate other lyso-
lipids; West et al., 1997; Aguado and Campbell, 1998; Lu et al.,
2005; Schmidt et al., 2010; Prasad et al., 2011; Eto et al., 2014).
In addition to the deﬁned LPAATs, other lyso-phospholipid acyl-
transferases are able to esterify LPA to some degree (Agarwal,
2012).
Another potential source of PA is mitochondrial phospholipase
D (MitoPLD), a divergent member of the PLD superfamily local-
ized to the OMM that can hydrolyze CL to PA in vitro (Choi et al.,
2006). Similar to yeast, mammals can also produce PA via the
dihydroxyacetone phosphate pathway in the peroxisome (Hajra
and Bishop, 1982). All of the discussed pathways of PA synthe-
sis are located outside of, or on the outside of, mitochondria.
However, the recent identiﬁcation of acylglycerol kinase (AGK)
in the IMS suggests that PA may be produced inside the mito-
chondrion (Hung et al., 2014). AGK, previously termed MuLK for
multi-substrate lipid kinase (Waggoner et al., 2004), phosphory-
lates diacylglycerol (DAG) and monoacylglycerol generating PA
and LPA (Waggoner et al., 2004; Bektas et al., 2005). AGK activ-
ity is modulated by surface charge (via Mg2+) and stimulated, in
a dose-dependent manner, by CL (Waggoner et al., 2004). More-
over, overexpression of AGK in the human prostate cancer PC-3
model results in increasedmitochondrial PA althoughCL levels are
unchanged (Bektas et al., 2005). Thus, whether PA made by AGK
inside of the mitochondrion can and does access the downstream
CL biosynthetic machinery is unclear.
CARDIOLIPIN BIOSYNTHESIS
Upon gaining access to the matrix side of the IMM (discussed
later), PA is converted to cytidine diphosphate-DAG (CDP-DAG)
and pyrophosphate upon reaction with cytidine triphosphate
(CTP; Figure 1). The reaction is catalyzed by CDP-DAG syn-
thases (CDSs), whose activities have been demonstrated in yeast
ER and mitochondria (Kuchler et al., 1986; Shen et al., 1996). It
has been recently established that the conserved IMM resident
Tam41p is the mitochondrial CDP-DAG synthase whose activity
provides CDP-DAG for CL biosynthesis (Tamura et al., 2006, 2013;
FIGURE 1 | Mammalian cardiolipin biosynthesis. CL biosynthesis likely
involves PA sourced from multiple pathways. PA can be generated by LPAATs
which acylate LPA; LPA can be made using glycerol 3-phosphate (G3P) and
acyl-CoAs by mitochondrial and ER GPATs. Additionally, PA can be made on
the OMM through the hydrolysis of CL by MitoPLD. In the OMM, PA recruits
the phosphatase lipin-1 which dephosphorylates PA into DAG. In turn, DAG
may trafﬁc across the OMM and be phosphorylated by AGK forming PA in the
context of the IMS-side of the IMM. Regardless of where it is made, PA must
reach the matrix side of the IMM to gain access to the core CL biosynthetic
machinery. Here, PA is converted to CDP-DAG byTAMM41, thus providing
the precursor for the committed step in CL biosynthesis, PGP synthesis by
PGS1. PGP is rapidly dephosphorylated by PTPMT1 and the produced PG is
condensed with CDP-DAG by CLS generating CL. Dashed arrows describe
uncharacterized steps and pathways.
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Kutik et al., 2008). Accordingly, CDS proteins in the ER provide
CDP-DAG that is used for phospholipid biosynthesis therein while
TAMM41 supplies the CL pathway (Horvath and Daum, 2013).
Also localized on the matrix-facing leaﬂet of the membrane
are downstream enzymes in PG and CL biosynthesis. The com-
mitted step of this pathway is catalyzed by phosphatidylglycerol
phosphate (PGP) synthase (PGS1), which forms PGP from
CDP-DAG and glycerol 3-phosphate (Chang et al., 1998a). After
PGP is synthesized, it is rapidly dephosphorylated to PG by
PTPMT1 (Xiao et al., 2011; Zhang et al., 2011) of the protein
tyrosine phosphatase family that shares no primary sequence
similarity to the yeast PGP phosphatase, Gep4p (Osman et al.,
2010). Notably, at steady state, PG is present at extremely low
levels (1–2%) relative to the other major mitochondrial phos-
pholipids (Daum, 1985), indicating that newly synthesized PG
is quickly consumed by downstream pathways. Finally, cardi-
olipin synthase (CLS), an integral IMM protein with its active
site facing the matrix (Schlame and Haldar, 1993), condenses PG
with another molecule of CDP-DAG to generate nascent unre-
modeled CL (Chang et al., 1998b; Chen et al., 2006; Lu et al.,
2006).
CARDIOLIPIN REMODELING
Cardiolipin biosynthetic enzymes exhibit no or only limited
acyl chain speciﬁcity (Chang et al., 1998b; Chen et al., 2006;
Houtkooper et al., 2006). The general lack of acyl chain speci-
ﬁcity in CL biosynthesis is signiﬁcant as it is in direct contrast
to the observation that in any given tissue [except the brain
(Cheng et al., 2008)], there exists a dominant homogeneous
molecular form of CL that is characterized by the incorpo-
ration of unsaturated fatty acyl chains (Schlame et al., 1993)
and molecular symmetry with respect to the two chiral centers
of CL (Schlame et al., 2005). In mammals, CL is predomi-
nantly composed of unsaturated 18-carbon linoleic acid (18:2).
The enrichment in this particular species is exempliﬁed by
human heart where 18:2-linoleic acid constitutes up to 90% of
the acyl chains in CL, yielding the abundant and stereotypi-
cal tetralinoleoyl-CL species (Schlame and Otten, 1991; Schlame
et al., 2005). However, it is notable that the ﬁnal acyl chain
composition of CL in different tissues is not the same; this
observation has led to the hypothesis that the ﬁnal acyl chain
composition of CL is tailored to the unique demands of its
host tissue (Schlame et al., 2005; Han et al., 2006; Cheng et al.,
2008).
As such, the generation of CL molecular species that accumu-
late at steady state requires the active remodeling of CL shortly after
its de novo synthesis (Eichberg, 1974; Schlame and Rustow, 1990).
To initiate the remodeling process, a lipase removes an acyl chain
from CL generating monolyso-CL (MLCL) that is subsequently
re-acylated by one of several enzymes (Figure 2). Through a series
of such reactions at each position in CL, a tissue-speciﬁc homoge-
neous pool of CL is generated that is characterized by molecular
symmetry and a higher degree of acyl chain unsaturation.
Phospholipases
In yeast, the recently identiﬁed cardiolipin deacylase, Cld1p, ini-
tiates CL remodeling and preferentially catalyzes the hydrolysis of
palmitic acid (16:0) from newly synthesized CL, forming MLCL
(Beranek et al., 2009; Baile et al., 2014b). In the absence of Cld1p,
the acyl chain composition of CL shifts to palmitic acid (16:0)
residues at the expense of palmitoleic (16:1) and oleic (18:1) acid
moieties (Beranek et al., 2009; Baile et al., 2014b). Cld1p associates
with thematrix-facing leaﬂet of the IMMand lacks anymembrane
spanning segments (Baile et al., 2013), placing the initiation of CL
remodeling on the same side of the IMM as its biosynthesis.
Although there are no orthologs of Cld1p in higher eukary-
otes, evidence points to Ca2+-independent phospholipases A2
(iPLA2) as being involved in mammalian CL remodeling. The
PLA2 family of enzymes catalyzes the hydrolysis of membrane
glycerophospholipids at the sn-2 position, generating free fatty
acids and lyso-lipids. Interestingly, all of the PLA2 isoforms capa-
ble of hydrolyzing CL in vitro have different speciﬁcities for CL
molecular species (Hsu et al., 2013).
iPLA2γ is membrane-bound, dually localized to the mito-
chondrion and peroxisome, and participates in CL metabolism
(Mancuso et al., 2000). In the hearts and skeletal muscle of
ipla2γ−/ − mice, CL levels are reduced and the acyl chain pat-
tern is altered (Mancuso et al., 2007; Yoda et al., 2010). However,
the absence of iPLA2γ in TAZ knockdown mice does not pre-
vent the accumulation of MLCL as predicted if iPLA2γ functions
immediately upstream of TAZ (Kiebish et al., 2013), the major
physiological CL remodeling enzyme.
Ablation of another mitochondrially localized iPLA2 family
member, iPLA2-VIA, in taz −/ − ﬂies, partially restores MLCL:CL
ratios, a biochemical hallmark of TAZ dysfunction, and rescues
male sterility (Houtkooper et al., 2009a,b; Malhotra et al., 2009a).
Still, the CL acyl chain pattern in single ipla2-via−/ − ﬂies is
not signiﬁcantly different from wild type (wt) ﬂies, suggesting
that like murine iPLA2γ, iPLA2-VIA activity is not obligately
required to initiate the remodeling process. Thus, which phos-
pholipase(s) functions upstream of mammalian TAZ remains
an open and important question. Once identiﬁed, basic bio-
chemical and cell biological characterization will further establish
the topology of CL remodeling. For instance, it is anticipated
that the lipase(s) that initiates CL remodeling will reside in
the same compartment as the enzyme that subsequently re-
acylates MLCL; it is worthwhile to note that although iPLA2γ
localizes to the mitochondrion, its submitochondrial distribu-
tion has not been formally demonstrated. If the lipase and its
substrate do not co-localize, then appropriate trafﬁcking steps
of the lipid substrate (CL or MLCL) will be inferred. A con-
sideration of the basic cell biology of the lipase(s) required
for CL remodeling is particularly relevant given that all three
enzymes that can re-acylate MLCL reside in distinct cellular
compartments.
Trans/acyltransferases
In mammals, there are at least three enzymes that have the capac-
ity to re-acylate MLCL: TAZ,MLCL acyltransferase 1 (MLCLAT1),
and acyl-CoA:lysocardiolipin acyltransferase-1 (ALCAT1), of
which only TAZ is evolutionarily conserved from yeast to higher
eukaryotes (Taylor and Hatch, 2003, 2009; Xu et al., 2006b; Clay-
pool and Koehler, 2012). All evidence to date indicates that the
MLCL transacylase, TAZ, is responsible for the vast majority of
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FIGURE 2 | Mammalian cardiolipin remodeling. CL that is synthesized
by CLS on the matrix-facing leaﬂet of the IMM can by remodeled by
three different pathways. While no single enzyme has been demonstrated
to be required to initiate CL remodeling in mammals, several
phospholipases of the iPLA2 family have been demonstrated to have a
role in the process. Additionally, the submitochondrial localization of the
phospholipases and the mechanisms by which CL gains access to these
enzymes are unknown. After a fatty acyl chain is hydrolyzed from CL,
generating MLCL, MLCL can be acylated back to CL by acyltransferases
or transacylases. MLCLAT1 on the matrix-leaﬂet of the IMM, TAZ on the
IMS-facing leaﬂets of the OMM and IMM, and ALCAT1 on the ER MAM
all have the capacity to re-acylate MLCL. The acyltransferases, ALCAT1
and MLCLAT1, use acyl-CoAs as an acyl chain donor to acylate MLCL. In
contrast, the transacylase TAZ uses acyl chains donated from other
phospholipids. The activity of TAZ is required to establish the steady state
physiological CL molecular form. In contrast, the CL formed by ALCAT1 is
more sensitive to oxidative damage and associated with pathologic states.
Dashed arrows describe uncharacterized steps and pathways. In the
phospholipid key, unremodeled CL corresponds to the newly synthesized
CL that enters the pathway at the point of CLS (black head group). CL
can undergo either physiologically relevant CL remodeling (green head
group) or pathological remodeling (red head group).
physiological CL remodeling. TAZ deﬁciency is biochemically
characterized by increased MLCL, the remodeling intermediate,
decreased CL, both the substrate and product, and an abnor-
mal acyl chain pattern of the remaining CL (Vaz et al., 2003; Gu
et al., 2004; Valianpour et al., 2005; Claypool et al., 2006, 2011;
Houtkooper et al., 2009a). However, the mechanism by which
TAZ establishes the steady state CL acyl chain composition is
unresolved; TAZ catalyzes a reversible transacylation that exhibits
no intrinsic acyl chain speciﬁcity, acts on acyl chains at both
sn-1 and sn-2 positions, and can use any number of phospho-
lipids and their lyso-derivatives as fatty acyl donors and acceptors,
respectively (Xu et al., 2006b; Malhotra et al., 2009b). Notably, het-
erologous expression of human TAZ in taz −/ − ﬂies or taz1
yeast generates CL with acyl chain patterns typical of Drosophila
melanogaster and yeast, respectively, and not humans (Vaz et al.,
2003; Xu et al., 2009). This suggests that the characteristic fatty
acid proﬁle of CL may not be conferred by the substrate speci-
ﬁcity of TAZ. Interestingly, recombinant ﬂy TAZ can generate
the physiologically relevant tetralinoleoyl-CL species from MLCL
but only under experimental conditions that promote non-bilayer
membranes (Schlame et al., 2012a). This suggests that unique
membrane physical states such as regions of high curvature, can
confer upon TAZ acyl chain speciﬁcity. Othermechanisms that are
hypothesized to play a role in the TAZ-based establishment of CL
molecular species include the speciﬁcity of enzymes immediately
upstream of TAZ that initiate the remodeling process and thus
dictate which substrates are available to TAZ (Baile et al., 2014b),
as well as the dietary intake of fatty acids (Stavrovskaya et al.,
2013).
Presently, the submitochondrial localization of endogenous
mammalian TAZ has not been documented. Yeast Taz1p asso-
ciates with the IMS-facing leaﬂets of the OMM and the IMM as
an interfacial protein (Brandner et al., 2005; Claypool et al., 2006;
Gebert et al., 2009). This is in sharp contrast to the deacylase,
Cld1p that initiates CL remodeling and is localized to the matrix-
facing IMM leaﬂet (Baile et al., 2013). Topologically, this means
that MLCL produced on the matrix side of the IMM in yeast has
to ﬂip across the membrane and/or be transported to the OMM,
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to access TAZ for remodeling (Baile et al., 2014a). As TAZ is the
only CL remodeling enzyme that is conserved in eukaryotes, it is
anticipated that mammalian TAZ will be similarly localized in the
organelle. Therefore, determining the submitochondrial localiza-
tion of the upstream phospholipase in mammals will establish
the CL and MLCL trafﬁcking steps needed to access TAZ for
remodeling (Baile et al., 2014a).
In mammals, MLCLAT1, which associates with the matrix
side of the IMM (Carpenter et al., 1992), does not encounter
the same problem of substrate access as TAZ. MLCLAT1 was
originally identiﬁed in porcine liver mitochondria as a 74-kDa
protein (Taylor and Hatch, 2003) that corresponds to the COOH
terminus of the human trifunctional protein (TFP) alpha (α)
(Taylor and Hatch, 2009). The TFP complex consists of α- and
β-subunits that catalyze the last three steps of mitochondrial long-
chain fatty acid beta-oxidation thus providing a signiﬁcant source
of cellular energy (Carpenter et al., 1992; Uchida et al., 1992).
Pathogenic mutations in either TFP subunit are associated with
beta-oxidation disorders, where patients suffer from cardiomy-
opathy and skeletal myopathy (IJlst et al., 1994; Sims et al., 1995;
Ushikubo et al., 1996). Interestingly, recombinant TFPα is soluble
when expressed alone, in contrast to its partner TFPβ, suggesting
that it may contain a function independent of its association with
TFPβ that may be described by MLCLAT1 (Fould et al., 2010).
Presently, the gene encoding MLCLAT1 has not been deﬁnitively
determined. That MLCLAT1 is likely a splice variant of TFPα is
suggested by the fact that knockdown using RNAi targeting the
NH2-terminal portion of TFPα, absent in MLCLAT1, reduces
TFPα, but not MLCLAT1 mRNA levels (Taylor et al., 2012). How-
ever, whether RNAi targeting a shared region between TFPα and
MLCLAT1 can reduce the expression of both genes has not been
established.
Both recombinant human TFPα and MLCLAT1 can bind
MLCL in vitro and are able to incorporate linoleoyl-(18:2), oleoyl-
(18:1), and palmitoyl-(16:1) CoA into MLCL (Taylor and Hatch,
2009; Fould et al., 2010; Taylor et al., 2012). When either pro-
tein is overexpressed in Barth syndrome (BTHS) lymphoblasts,
there is increased incorporation of linoleic acid in CL (Taylor and
Hatch, 2009; Taylor et al., 2012). However, TFPα overexpression
does not generate a CL proﬁle that reﬂects its in vitro speciﬁcity.
Thus, while TFPα and/or MLCLAT1 can participate in CL remod-
eling, especially in the absence of TAZ function when the levels of
MLCL are high, the exact contribution of this acyltransferase(s) to
physiological CL remodeling is unclear.
Finally, ALCAT1 acylates MLCL and dilyso-CL in vivo and
can use a number of lyso-phospholipids as acyl acceptors in vitro
(Cao et al., 2004, 2009; Zhao et al., 2009). Depending on the acyl
acceptor, tissue type, and species, ALCAT1 has been described to
preferentially incorporate long-chain unsaturated fatty acyl chains
or promiscuously accept all acyl-CoA derivatives (Cao et al., 2004;
Zhao et al., 2009). As such, ALCAT1 lacks the speciﬁcity expected
of an enzyme with a critical role in physiological CL remodel-
ing. Notably, ALCAT1 resides in the ER MAMs (Cao et al., 2004;
Zhao et al., 2009). Therefore, for ALCAT1 to participate in CL
metabolism, CL and/or MLCL must travel from the IMM to at
least the external leaﬂet of the OMM, if the active site of ALCAT1,
which has not been determined, faces the cytosol.
The absence of TAZ causes alterations in CL molecular species
in every model tested to date (Vreken et al., 2000; Bissler et al.,
2002; Valianpour et al., 2002, 2005; Schlame et al., 2003, 2005; Vaz
et al., 2003; Gu et al., 2004; Xu et al., 2005, 2006a,b; vanWerkhoven
et al., 2006; Acehan et al., 2009, 2011b; Houtkooper et al., 2009a,b;
Dudek et al., 2013; Gonzalvez et al., 2013; Baile et al., 2014b; Wang
et al., 2014a). In contrast, the loss of MLCLAT1/TFPα or ALCAT1
does not consistently result in changes in the steady state acyl
chain composition of CL (Li et al., 2010; Schlame et al., 2012b;
Richter-Dennerlein et al., 2014). Thus, it is unlikely that either
MLCLAT1/TFPαorALCAT1 signiﬁcantly contributes to the steady
state CL acyl chain proﬁle under normal conditions. These results
further underscore the predominant role of TAZ in physiological
CL remodeling.
PHOSPHOLIPID TRAFFICKING STEPS REQUIRED FOR CL METABOLISM
Once made, PA must travel to the matrix side of the IMM
to gain access to the CL biosynthetic machinery. If made in
the ER, this requires movement of PA from ER to OMM, ﬂip-
ping between OMM leaﬂets, movement from the OMM to the
IMM, and ﬁnally ﬂipping to the matrix-facing IMM leaﬂet.
Inter-organelle contacts have recently emerged as being critically
important for mitochondrial phospholipid metabolism. In yeast,
there are at least two distinct structures that contribute to the
physical association of ER and mitochondria (Figure 3). The
ﬁrst described complex is the ER-mitochondria encounter struc-
ture (ERMES; Kornmann et al., 2009). A second ER-mitochondria
tether, the ER-membrane protein complex (EMC), that is dis-
tinct from ERMES, was recently identiﬁed in yeast (Lahiri et al.,
2014). When either EMC or ERMES subunits are missing, the
number and length of ER-mitochondria contacts are reduced
and mitochondria are unable to support growth on respiratory
media (Kornmann et al., 2009, 2011; Tamura et al., 2012; Lahiri
et al., 2014). Also, a synthetic mitochondria-ER tether similarly
rescues the defects caused by the absence of EMC or ERMES.
While EMC may play a more direct role in phospholipid trafﬁck-
ing (Lahiri et al., 2014), EMC and ERMES complexes likely have
both overlapping and distinct functions in phospholipid trans-
fer between the ER and mitochondria (Nguyen et al., 2012; Lahiri
et al., 2014).
The ERMES subunits are conserved in fungi but not in
metazoans. In contrast, the close apposition of ER and mito-
chondria is conserved (Csordas et al., 2006). In mammals, IP3
receptor/GRP75/VDAC1-containing complexes (Matsuzaki et al.,
2013), mitofusin-2 (de Brito and Scorrano, 2008), and several
other proteins have roles in ER-mitochondria tethering (Merk-
wirth and Langer, 2008; Csordas et al., 2010). Moreover, the newly
described EMC is conserved but its role in ER-mitochondrion
tethering has only been tested in yeast. The diversity of play-
ers implicated in this inter-organelle association provides strong
evidence of the physiological importance of such contacts.
The existence of vacuolar and mitochondrial contacts, termed
vCLAMPs (vacuole and mitochondrial patch), recently identi-
ﬁed in yeast, further highlights the importance of inter-organelle
associations for mitochondrial phospholipid metabolism (Elbaz-
Alon et al., 2014; Honscher et al., 2014). Simultaneous deletion of
ERMES and vCLAMP components is synthetically lethal. Deletion
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FIGURE 3 | Inter-organelle and intra-organelle phospholipid trafficking.
The existence of ER- and vacuole-mitochondria contacts is highly conserved
from yeast to humans. By generating closely appositioned membranes, the
inter-organelle and intra-organelle tethers are hypothesized to promote
movement of lipids across the aqueous cytosol and IMS, respectively. Within
the mitochondrion, phospholipid trafﬁcking may involve contacts between the
OMM and the IMM mediated by MICOS complexes or NM23-H4. In addition,
PRELI transports PA from the OMM to the IMM. PLS3 activity stimulates CL
externalization on OMM. It may directly transport CL from the IMM to the
OMM or instead function as a scramblase that redistributes CL between both
leaﬂets of the IMM. CL now exposed to IMS-side of IMM would then be
transported to the OMM by other mechanisms.With the possible exception
of EMC, it is presently unclear if any of the known tethers has speciﬁcity for a
deﬁned phospholipid(s); as such, they are shown to promote the ﬂux of
phospholipids (PLs) in bulk. If a speciﬁc phospholipid is impacted by
mutations in a complex/protein (levels and/or composition), the lipid is
indicated. Solid lines indicate known transport mechanisms. Dashed lines
describe possible trafﬁcking routes and/or highlight transport events whose
mechanisms have not been resolved. The ERMES complex is found only in
yeast and color-coded pink. For the remaining proteins/complexes, those
found only in mammals are in blue and those that are likely to be conserved
across species are colored gray. See text for additional details.
of vCLAMP and repression of ERMES impairs PA trafﬁcking
into mitochondria and results in a 40% reduction in CL levels
(Elbaz-Alon et al., 2014). A recent report describing mitofusin-2-
mediated contacts between mouse melanosomes (a lysosomal-like
compartment in pigment cells) and mitochondria (Daniele et al.,
2014), suggests that there may be similar vacuolar-tethering
mechanisms in mammals.
Analogous to inter-organelle tethers, regions of close physical
apposition between the IMM and OMM are important for lipid
trafﬁcking across the IMS (Ardail et al., 1990; Schlattner et al.,
2014), although the underlying mechanism(s) is unknown. In
addition, IMM-OMM contact sites have roles in energy trans-
duction from the mitochondrial matrix to the cytosol (Nicolay
et al., 1990) and precursor protein import (Vogel et al., 2006).
MICOS (mitochondrial contact site and cristae organizing sys-
tem) is a hetero-oligomeric protein complex that is embedded
in the IMM but interacts with several distinct OMM proteins
(Harner et al., 2011; Hoppins et al., 2011; von der Malsburg et al.,
2011; van der Laan et al., 2012; Pfanner et al., 2014). Depletion
of the conserved mitoﬁlin/Fcj1p (yeast formation of cristae junc-
tion 1) subunit, which constitutes the MICOS core, results in an
expanded IMM surface, dramatic loss of cristae junctions, and
the remaining cristae are stacked, lamellar, and aberrantly discon-
nected from the OMM (John et al., 2005; Mun et al., 2010; Harner
et al., 2011; von der Malsburg et al., 2011). Recently, apolipopro-
tein O (APOO) and APOO-like protein (APOOL) were identiﬁed
as potential subunits of the bovine MICOS complex (Weber et al.,
2013). The IMS-facing APOOL speciﬁcally binds CL in vitro
and its knockdown results in morphological phenotypes similar
to yeast MICOS mutants (Weber et al., 2013). Thus, MICOS com-
plexes are key determinants of cristae morphology that contain
subunits capable of bindingCL (Harner et al., 2011; Hoppins et al.,
2011; von der Malsburg et al., 2011). Whether these two properties
are leveraged in the context of phospholipid trafﬁcking between
the IMM and OMM is presently unclear although it is interesting
to note that biochemically isolated IMM-OMM contact sites are
enriched in CL (Ardail et al., 1990; Simbeni et al., 1991).
The movement of PA from the OMM to the IMM is medi-
ated by the IMS-resident Ups1p/PRELI-like proteins (Connerth
et al., 2012; Potting et al., 2013). In vitro, the yeast Ups1p/Mdm35p
dimer (Potting et al., 2010; Tamura et al., 2010) binds numerous
anionic phospholipids but only transports PA (Connerth et al.,
2012). The directionality of PA transport is likely conferred by
the fact that Ups1p remains tightly bound to membranes contain-
ing physiological amounts of CL, leading to Ups1p’s subsequent
degradation. These observations suggest a mechanism for regu-
lating CL biosynthesis by limiting precursor trafﬁcking between
the two membranes when CL levels are bountiful (Connerth et al.,
2012). Whether transport of PA by the Ups1p/PRELI-like pro-
teins utilizes in some manner MICOS or is instead mechanistically
distinct is at present unknown.
Once PA is transported to the IMM, or if synthesized in
this compartment by AGK, the transbilayer movement of PA to
the matrix-leaﬂet is required for PA to gain access to the CL
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biosynthetic enzymes. How this is achieved is presently not known
but could involve a speciﬁc protein or protein complex. However,
the requirement for a speciﬁc PA transporter does not seem obli-
gate as a transmembrane pH gradient is sufﬁcient to disseminate
PA across both IMM leaﬂets (Hope et al., 1989; Gallet et al., 1999).
Since CL is made in the context of the matrix-leaﬂet and
can eventually be exposed on the OMM, mechanisms must be
present to facilitate the movement of CL intra-mitrochondrially.
Scramblases are Ca2+-dependent, ATP-independent bidirectional
transporters that equilibrate lipids unevenly distributed across
a bilayer (Contreras et al., 2010). As such, a scramblase could
serve to redistribute CL made on the matrix side, between IMM
leaﬂets. Alternatively, phospholipid translocation between mem-
brane leaﬂetsmay not bemediated by speciﬁc proteins, but instead
facilitated by the presence of numerous transmembrane proteins
(especially in the context of the IMM) in a non-speciﬁc manner,
as suggested for bacterial and ER membranes (Kol et al., 2001,
2004).
Albeit minor, CL is a normal constituent of the OMM and
can trafﬁc to the OMM following certain stimuli (Gonzalvez et al.,
2008; Chu et al., 2013). Phospholipid scramblase 3 (PLS3) is the
only knownmitochondrial scramblase (Zhou et al., 1998; Liu et al.,
2003a; Van et al., 2007) and in vitro, murine and human PLS3
catalyze the Ca2+-dependent ﬂip-ﬂop of CL in proteoliposomes
(Zhou et al., 1998). However, it is unclear whether PLS3 functions
in vivo as a CL scramblase or instead mediates the movement of
CL from the IMM to the OMM. PLS3 overexpression increases
mitochondrial mass, CLS transcription, CL synthesis, and CL
externalization to the OMM (Liu et al., 2003b; Van et al., 2007).
Conversely, overexpression of a catalytically dead pls3 allele or
PLS3 knockdown reduces CL externalization following UV irra-
diation or rotenone poisoning, respectively (Liu et al., 2003b; Chu
et al., 2013). How does PLS3 activity contribute to movement of
CL to the OMM? If PLS3 is a true scramblase, then the equilibra-
tion of CL between the leaﬂets of the IMM may be required for the
subsequent ability of CL to trafﬁc to theOMM.Alternatively, PLS3
may instead directly participate in the movement of CL between
mitochondrial membranes. Future studies are needed to clarify
the role of PLS3 in this process.
Another potential mechanism by which lipids can be
transferred from the IMM to the OMM involves the
NM23-H4/NDPK-D (nucleotide diphosphate kinase isoform D;
Milon et al., 2000). NM23-H4 is the only mitochondrially targeted
member of a family of NDPKs whose role in phosphotransfer
is well-established. NM23-H4 has been additionally implicated
in the trafﬁcking of anionic phospholipids (in particular CL)
between the IMM and the OMM (Tokarska-Schlattner et al.,
2008). Interestingly, the levels of CL can functionally switch
NM23-H4 between phosphotransfer and lipid transfer modes
(Schlattner et al., 2013). Normally, the lipid transfermode is inhib-
ited by anionic lipids, including CL, and the protein operates as
a nucleotide kinase. However, when CL levels are low (due to
mitochondrial dysfunction), NM23-H4’s lipid transfer function
is de-repressed and the protein cross-links the IMS-facing leaﬂets
of the IMM and OMM. Subsequently, NM23-H4 facilitates the
thermodynamically unfavorable movement of negatively charged
lipids across the aqueous IMS.
While a role for both NM23-H4 and PLS3 in the stimulated
externalization of CL on the OMM is clearly emerging, whether
either or both enzymes participate in the routine processes of
CL biosynthesis and remodeling is not known. Given its MAM-
residence, it is tempting to speculate that NM23-H4 and/or PLS3
may be involved in ALCAT1-based CL remodeling.
PHYSIOLOGICAL FUNCTIONS
Phospholipids play a myriad of roles in cellular and mitochon-
drial physiology that are beyond the scope of any single review.
The following section is focused on recently discovered roles and
guided by those physiological functions of mitochondrial lipids,
that when disturbed, may contribute to human disease. Of note,
the diversity of functions attributed to the discussed mitochon-
drial phospholipids is reﬂected by the vast array of pathogenic
mechanisms that underlie this cohort of mitochondrial diseases.
PHOSPHATIDIC ACID
The dynamic appearance and disappearance of PA on the OMM
is a recently established determinant of mitochondrial fusion and
ﬁssion. Overexpressed MitoPLD generates PA on the OMM, pro-
moting mitochondrial fusion and subsequent aggregation (Choi
et al., 2006), while loss of MitoPLD leads to fragmented mito-
chondria (Huang et al., 2011). PA generated by MitoPLD recruits
the PA phosphatase, lipin-1. Lipin-1 dephosphorylates PA to
DAG which stimulates mitochondrial ﬁssion while simultane-
ously removing the pro-fusogenic accumulation of PA on the
OMM (Reue and Dwyer, 2009; Huang et al., 2011). Interest-
ingly, mitopld−/ − ﬂies (Pane et al., 2007) and mice (Huang
et al., 2011; Watanabe et al., 2011) have defects in the biogen-
esis of Piwi-interacting (pi)RNAs that have a role in provid-
ing a germline-speciﬁc defense against retrotransposon activity
(Gunawardane et al., 2007). Male mitopld−/ − ﬂies are sterile,
typical of ﬂies lacking piRNAs (He et al., 2009), lose nuages
(Russell and Frank, 1978), sites where piRNA production and
processing is thought to occur, and have de-repressed retro-
transposons in their testes (Pane et al., 2007; Watanabe et al.,
2011). Moreover, lipin-1−/ − mice have elevated PA on the
mitochondrial surface and signiﬁcantly increased nuage forma-
tion (Huang et al., 2011). Genetic evidence therefore strongly
supports a role for PA and/or DAG at the OMM in piRNA
production (Huang et al., 2011). However, the exact role of Mito-
PLD with respect to the mitochondrial phospholipid pool is
unclear.
The importance of the dynamic regulation of PA on the OMM
is further substantiated by the recent characterization of PA-PLA1
(Baba et al., 2014). In vitro, PA-PLA1 preferentially deacylates
PA to LPA (Higgs and Glomset, 1994). PA-PLA1 overexpression
or depletion in HeLa cells causes mitochondrial fragmentation
and elongation, respectively (Baba et al., 2014). Interestingly, co-
expressionof PA-PLA1 andMitoPLDprevents the accumulationof
PA on the OMM surface and the morphological defects associated
with MitoPLD overexpression alone (Baba et al., 2014). Similar to
mitopld−/ −and lipin-1−/ − mice, pa-pla1 −/ − mice have a defect
in spermatogenesis that correlates with mitochondrial disorgani-
zation (Baba et al., 2014). Finally, diminution of ddhd2, a related
iPLA1 family member with a similar speciﬁcity for PA as PA-PLA1,
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causes mitochondrial elongation in mouse embryonic ﬁbroblasts
(Baba et al., 2014).
PHOSPHATIDYLGLYCEROL
Besides being a required intermediate in CL biosynthesis, PG
is also a precursor for bis(monoacylglycerol)phosphate (BMP;
Hullin-Matsuda et al., 2007), a class of phospholipid that is highly
enriched in late endosomes and lysosomes (Wherrett and Huterer,
1972; Poorthuis and Hostetler, 1976; Mobius et al., 2003). While
BMP is found in many tissues and cells, it is usually present at
less than 1% of the total phospholipid mass (Simon and Rouser,
1969; Mason et al., 1972). BMP is a structural isomer of PG and is
thought to function in the maintenance and regulation of endo-
somal/lysosomal membrane dynamics and cholesterol trafﬁcking
(Kobayashi et al., 1998, 1999; Hullin-Matsuda et al., 2009; Gal-
lala and Sandhoff, 2011). However, its exact biological role(s) is
unresolved.
CARDIOLIPIN
The absolute requirement of PG and/or CL for life is under-
scored by the observation that ptpmt1−/ − mice die in utero before
embryonic day 8.5 (Zhang et al., 2011). Reﬂecting this impor-
tance, CL has a multitude of functional roles in mitochondria
(Figure 4). CL is highly enriched in cardiac tissues making up
15–20% of the total phospholipid phosphorus mass of the heart
(Pangborn, 1942; Hostetler et al., 1975). Its relative abundance in
cells and tissues with high energetic demands point to CL as being
intimately involved in maintaining mitochondrial structure and
function. Indeed, it interacts with numerous mitochondrial pro-
teins, including all OXPHOS complexes and most mitochondrial
solute carriers, and is often required for their functional reconsti-
tution in liposomes (Cheneval et al., 1983; Beyer and Klingenberg,
1985; Eble et al., 1990; Shinzawa-Itoh et al., 2007; Claypool et al.,
2008; Claypool, 2009; Schwall et al., 2012). In addition, CL is pro-
posed to function as a proton trap that helps funnel pumped
protons toward the ATP synthase to generate ATP (Haines and
Dencher, 2002). An association with CL promotes the assembly
of membrane proteins into oligomeric complexes (Zhang et al.,
2002; Pfeiffer et al., 2003; Claypool et al., 2008; Strauss et al.,
2008; Acehan et al., 2011a; Althoff et al., 2011). Indeed, CL is
important for the assembly and function of IMM and OMM
translocases and thus, mitochondrial biogenesis (Jiang et al., 2000;
van der Laan et al., 2007; Gebert et al., 2009). CL is also criti-
cally important for stabilizing respiratory supercomplexes (SCs),
supramolecular assemblies built from respiratory complexes I, III,
and IV (Schagger and Pfeiffer, 2000). These SCs are thought to
increase the efﬁciency of electron transfer between the respiratory
chain components by substrate channeling mechanisms (Acin-
Perez et al., 2008; Lapuente-Brun et al., 2013), thereby maximizing
OXPHOS. Further, SC assembly shortens the distance traveled by
mobile electron carriers, minimizing ROS leakage and reducing
oxidative damage. Finally, CL-binding stimulates the activity of
dynamin-related GTPases with pivotal roles in IMM fusion and
mitochondrial ﬁssion (Ban et al., 2010; Montessuit et al., 2010;
Bustillo-Zabalbeitia et al., 2014). All of these CL-supported func-
tions have been discussed extensively in several excellent reviews
(Chicco and Sparagna, 2007; Houtkooper and Vaz, 2008; Joshi
et al., 2009; Lewis and McElhaney, 2009; Sparagna and Lesnefsky,
2009; Osman et al., 2011; Claypool and Koehler, 2012).
Both apoptosis and mitophagy, a macro-autophagic process
that is pre-emptive to cell death via apoptosis, are signaled in
part by the externalization of CL to the OMM. The movement
of CL to the OMM is thought to involve the scramblase PLS3
and/or NM23-H4 and may occur preferentially at IMM-OMM
contact sites thought to be enriched in CL (Ardail et al., 1990;
Simbeni et al., 1991). Overexpression of NM23-H4, but not a
CL-binding mutant, increases apoptotic markers that may be
ascribed to increased CL externalization on the OMM (Schlat-
tner et al., 2013). CL on the OMM attracts and activates caspase-8
(Gonzalvez et al., 2008) and aids in pro-apoptotic Bax insertion
into and permeabilization of the OMM (Kuwana et al., 2002;
Lucken-Ardjomande et al., 2008). In preparations of giant unil-
amellar vesicles lacking CL, caspase-8 is unable to interact with
vesicle membranes, a step necessary for caspase-8 activation
and subsequent recruitment of tBid (Jalmar et al., 2010, 2013).
Yeast mitochondria lacking CL are protected from the bioener-
getic perturbations normally induced upon incubation with tBid
(Gonzalvez et al., 2005) underscoring the importance of CL for
tBid function. Furthermore, CL peroxidation by cytochrome c
promotes the release of a number of pro-apoptotic factors, includ-
ing cytochrome c, following OMM permeabilization (Kagan
et al., 2005). Under conditions of mild mitochondrial dysfunc-
tion, CL is externalized on the OMM where it promotes the
speciﬁc destruction of the mitochondrion by mitophagy (Chu
et al., 2013). siRNA knockdown of the scramblase PLS3 or CL syn-
thase CLS in neuronal cells, diminishes CL externalization and the
number of mitochondrially-associated autophagic markers, and
attenuates chemically-induced mitophagy (Chu et al., 2013). As
CL externalization is important for both apoptosis andmitophagy,
there is likely to be a threshold level of mitochondrial dam-
age (severity of insult and percentage of mitochondrial pool
impacted) above which apoptosis is executed and below which
the affected mitochondria are selectively removed. In addition,
qualitative and/or quantitative differences in the CL exposed on
the OMM may inﬂuence how this lipid signal is interpreted by
the cell.
REMODELED VERSUS UNREMODELED CL
While the role and functional consequence of MLCAT1-based
remodeling is presently unresolved, TAZ- and ALCAT1-mediated
CL remodeling are associated with very different physiologic out-
comes. In the absence of TAZ, the acyl chain composition of CL is
signiﬁcantly diversiﬁed and molecular symmetry is lost (Schlame
et al., 2005). Thus, TAZ has a preeminent role in dictating the ﬁnal
collection of acyl chains attached to CL under physiological con-
ditions. The ﬁnal acyl chain pattern of CL, which is tissue-speciﬁc,
is thought to be critical for normal mitochondrial physiology
by supporting some combination of the functions attributed to
CL. However, cld1 yeast, which fail to initiate CL remodeling
and accumulate normal amounts of unremodeled CL, have wt
OXPHOS activity and normal mitochondrial morphology (Baile
et al., 2014b; Ye et al., 2014a). These results question the idea
that TAZ-based CL remodeling produces “optimized” CL species
that promote mitochondrial ﬁtness, and instead suggests that CL
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FIGURE 4 | Biological functions of cardiolipin. As the signature
phospholipid of the mitochondrion, CL is intimately involved in a number of
mitochondrial processes. (A) Anionic CL on the IMM can function as a proton
trap by attracting (and providing) a local pool of protons that can be funneled
towards the ATP synthase. Moreover, CL is associated with every OXPHOS
component and can promote their assembly into respiratory supercomplexes.
Such supramolecular assemblies are thought to enhance electron transfer
and reduce ROS leakage from the electron transport chain. (B) CL associates
with dynamin-related GTPases that are intimately involved in fusion and
ﬁssion and (C) contributes to the assembly and function of IMM and OMM
translocases vital for mitochondrial biogenesis. (D) Besides enhancing
OXPHOS by stabilizing SCs, CL also promotes the assembly of ATP synthase
oligomers that provide a structural scaffold required for establishing the
characteristic shape of mitochondrial cristae. (E) Externalization of CL on the
surface of the mitochondrion is involved in signaling the execution of either
mitophagy or apoptotic cell death.
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remodeling may actually accomplish other physiologically impor-
tant functions that either were not tested (Baile et al., 2014b; Ye
et al., 2014a) or have not yet been discovered.
In contrast to TAZ-based CL remodeling, CL remodeled
by ALCAT1 predisposes mitochondria to damage. In mouse
myoblasts, ALCAT1 overexpression increases the amount of CL
enriched with docosahexaenoic acid (22:6) at the expense of
linoleic acid (18:2; Li et al., 2010), consistent with alterations
in CL species that are observed in aging rat hearts [the lat-
ter additionally contain 20:4 arachidonic acid (Paradies et al.,
2009)]. The increased acyl chain unsaturation in these CL forms
makes them peroxidation-prone and increases the susceptibil-
ity of mitochondria to undergo apoptosis (Watkins et al., 1998;
Paradies et al., 2009; Li et al., 2010). As such, ALCAT1 seems
to perform “pathogenic” remodeling of CL. Consistent with
this, ALCAT1 overexpression, also noted in mouse models of
metabolic disease, increases the rate of ATP, and consequently,
ROS production during oxidative stress (Li et al., 2010). Con-
versely, ablation of ALCAT1 elevates tetralinoleoyl-CL content
in the heart (Li et al., 2010), prevents the onset of disease,
increases insulin resistance, mitigates OXPHOS dysfunction by
increasing complex I activity, restores mtDNA ﬁdelity, allevi-
ates fusion defects and associated mitochondrial fragmentation,
and re-establishes mitochondrial quality control (Li et al., 2010,
2012; Liu et al., 2012; Wang et al., 2014b). Combined, this sug-
gests that CL remodeled by ALCAT1 may exacerbate and/or signal
mitochondrial dysfunction in disease pathogenesis (Wang et al.,
2014b).
EMERGING DISEASES OF MITOCHONDRIAL PHOSPHOLIPID
METABOLISM
With the recent application of next generation sequencing
methodologies, new disease-causing genes are being implicated
in mitochondrial disorders each year. For the remainder of this
review, we describe a new category of mitochondrial disorder
that is caused by nuclear defects that speciﬁcally alter mitochon-
drial phospholipid metabolism. We anticipate that the diseases
discussed below represent the tip of the iceberg and that more dis-
orders that impinge on mitochondrial phospholipid metabolism
will be identiﬁed in the near future.
TAZ MUTATIONS LEADING TO BARTH SYNDROME
Mutations in the gene that encodes the MLCL transacylase,
TAZ, lead to BTHS (Barth et al., 1983, 2004; Bione et al., 1996).
BTHS is the founding member of this new class of mitochon-
drial disease and thus not surprisingly, is the best characterized.
This X-linked multisystem disorder presents with cardiomyopa-
thy, skeletal muscle weakness, neutropenia, growth retardation,
and 3-methylglutaconic aciduria (3-MGA), and can be fatal if
not diagnosed early [Barth et al., 1983; Kelley et al., 1991; John-
ston et al., 1997; one isolated case of BTHS in a female patient
has been reported (Cosson et al., 2012)]. 3-MGA is a heteroge-
neous group of syndromes characterized by an increased excretion
of 3-methylglutaconic and 3-methylglutaric acids, breakdown
products of leucine catabolism (Wysocki et al., 1976). Additional
features such as isolated left ventricular non-compaction, ventric-
ular arrhythmia, motor delay, exercise intolerance, poor appetite,
fatigue, hypoglycemia, lactic acidosis, and hyperammonemia have
also been described in BTHS patients (Ichida et al., 2001; Stew-
ard et al., 2010). Patient heart, liver, and skeletal muscle biopsies
contain malformed mitochondria with tightly stacked or circular
bundles of cristae (Barth et al., 1983;Hodgson et al., 1987; Orstavik
et al., 1998; Bissler et al., 2002). In patient-derived lymphoblasts,
mitochondria have dramatically reduced inner membranes, col-
lapsed cristae, and are often fragmented (Xu et al., 2005; Acehan
et al., 2007). TAZ (G4.5) contains 11 exons, is localized on a gene-
rich region on Xq28, and is highly expressed in cardiac and skeletal
tissues (Bione et al., 1996). Pathogenic taz variants identiﬁed to
date encompass splice site mutations, insertions, deletions, as well
as missense and nonsense mutations (Johnston et al., 1997; a cur-
rent list of known genetic variants is maintained by the BTHS
foundation; https://www.barthsyndrome.org/science).
Efforts to understand BTHS pathogenesis are complicated by
the complete lack of genotype–phenotype correlations. Patients
with the same mutation, or even siblings sharing the same muta-
tion, can manifest with extremely disparate symptoms. A case in
point is that of a 51 years old proband, the oldest BTHS patient
reported, and his 3 years old grandnephew (Ronvelia et al., 2012).
Although they harbor the same mutation, the boy presented with
cardinal manifestations of BTHS (including congestive heart fail-
ure that required a heart transplant at 11 months of age) while the
great uncle was 43 years old when he was diagnosed with myopa-
thy. These observations highlight the importance of modifying
factors as key determinants in BTHS disease progression.
Furthermore, links between different mutations and severity
of disease have not been established for BTHS. Model organ-
isms can help bridge this gap. Using a yeast BTHS model, 21
distinct pathogenic missense mutations have been modeled in
yeast Taz1p and their loss-of-function mechanism deﬁned. This
effort has identiﬁed seven classes of BTHS mutants deﬁned by
their loss-of-function mechanisms (Claypool et al., 2006, 2011;
Whited et al., 2013). Brieﬂy, the seven classes comprise of vari-
ants that are (1) non-functional truncated products resulting
from frameshifts or aberrant splicing, (2) mislocalized within
mitochondria and aggregation-prone, (3) aberrantly assembled,
(4) catalytically dead, (5) hypomorphic alleles with residual
transacylase activity, (6) unable to engage in stable productive
assemblies, or (7) temperature-sensitive. Systematic analyses of
pathogenic variants in this manner can provide important mech-
anistic insight into the clinical heterogeneity of BTHS. The next
step in attaining this goal is to verify that the deﬁned loss-of-
functionmechanisms are conserved in an appropriatemammalian
model. Such a model is additionally needed to characterize
pathogenic alleles that cannot be modeled in yeast due to a lack of
conservation.
There are a number of BTHS models presently available.
Importantly, every BTHSmodel has the characteristic biochemical
defects that underlie BTHS – increased MLCL, decreased CL, and
an abnormal acyl chain composition of the remaining CL. In addi-
tion to yeast, other cellular BTHS models include patient-derived
ﬁbroblasts (Barth et al., 1996), lymphocytes (Schlame et al., 2005;
Xu et al., 2005), and iPSCs (Dudek et al., 2013; Wang et al., 2014a),
and TAZ-depleted rodent (Acehan et al., 2009; He, 2010; He et al.,
2014) andhumancell lines (Gonzalvez et al., 2008). Animalmodels
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of BTHS include TAZ-depleted zebraﬁsh (Khuchua et al., 2006)
and mice (Acehan et al., 2011b; Soustek et al., 2011; Phoon et al.,
2012), and taz −/ − ﬂies (Xu et al., 2006a).
Cellular models of BTHS show dysmorphic changes in mito-
chondrial morphology and energetic defects (Acehan et al., 2007,
2009; Gonzalvez et al., 2013). In patient-derived lymphoblasts (Xu
et al., 2005; Gonzalvez et al., 2013), iPSCs (Dudek et al., 2013),
and ﬁbroblasts (Barth et al., 1996), there is low basal respira-
tion, reduced membrane potential, and compromised coupling
of OXPHOS. Respiratory SCs are decreased and there is a shift
in SC assembly from large “respirasomes” to smaller, and pre-
sumably, less efﬁcient SCs (McKenzie et al., 2006; Dudek et al.,
2013; Gonzalvez et al., 2013). Therefore, it is postulated that
these alterations in respiratory chain assembly diminish respi-
ratory efﬁciency and consequently, augment ROS production.
While basal respiration is unaffected in the shRNA-inducible TAZ
knockdown mouse, maximal uncoupled respiration is reduced;
whether this reﬂects changes in respiratory SC stability has not
been demonstrated (Powers et al., 2013). Enzymatic analyses of
respiratory chain complexes using cardiomyocytes derived from
the TAZ knockdown mouse indicate that complex III is impaired
(Powers et al., 2013), suggestive of a similar bioenergetic dys-
function as noted in the cellular models. In TAZ-depleted mice
(Acehan et al., 2011b; Soustek et al., 2011; Phoon et al., 2012)
and zebraﬁsh (Khuchua et al., 2006), cardiac defects are observed
that recapitulate many of the relevant cardiac parameters noted
in BTHS patients. With respect to zebraﬁsh, TAZ knockdown
severely impairs zebraﬁsh development and the degree of cardiac
dysmorphology is proportional to the morpholino dose. In addi-
tion to impaired cardiac function, TAZ knockdown mice have
abnormal skeletal muscle ultrastructure (Xu et al., 2006a; Acehan
et al., 2011b) consistent with taz−/ − ﬂies that also have impaired
muscle functions (Xu et al., 2006a; Acehan et al., 2009). Recently,
cardiomyocytes differentiated fromBTHS patient iPSCs have been
generated (Dudek et al., 2013; Wang et al., 2014a). In these cells,
there is structural destabilization of respiratory SCs that corre-
lates with reduced respiratory complex activities (Dudek et al.,
2013). When wt cells are seeded onto engineered chips, they
form sarcomeres and contract; in contrast, the ability of BTHS-
derived cardiomyocytes to form organized sarcomeric arrays is
severely impacted as is their contractility (Wang et al., 2014a).
Therefore, results from the myriad of BTHS models indicate
that the lipid abnormalities that occur in the absence of TAZ
result in OXPHOS dysfunction associated with SC destabiliza-
tion. OXPHOS dysfunction increases the production of ROS and
in sum, these impairments compromise heart development and
function.
As already discussed, the stimulated externalization of CL onto
the OMM is an important event that can alternatively trigger
apoptosis or mitophagy. It is thus notable that BTHS-derived lym-
phocytes are resistant to mitochondrial-dependent apoptosis due
to an impaired ability to recruit and activate caspase-8 (Gonza-
lvez et al., 2008, 2013). Interestingly, caspase-8−/ − mice die in
utero and the embryos have heart abnormalities that include thin
and disorganized trabeculae (Varfolomeev et al., 1998), pheno-
types also observed upon TAZ depletion in utero (Phoon et al.,
2012). Thus, defects in caspase-8 activity may contribute to the
cardiomyopathy in BTHS. The relative capacity of BTHS mito-
chondria to be consumed by mitophagy has not been reported.
However, BTHS lymphocytes have more mitochondria that are
individually less functional (Gonzalvez et al., 2013) suggesting that
mitochondrial homeostasismay indeed be perturbed in BTHS and
contribute to disease progression.
Importantly, the detailed biochemical and cell biologic charac-
terization of the numerous BTHS models have begun to identify
potential avenues for therapeutic intervention. For instance, sup-
pression of mitochondrial ROS attenuates the energetic and
functional decline caused by TAZ-depletion in rodent cardiac
myocytes (He et al., 2014) and corrects the sarcomere organiza-
tion and contractile function of induced BTHS cardiomyocytes
(Wang et al., 2014a). Genetic and/or pharmacologic targeting of
the lipase that initiates CL remodeling in yeast, ﬂies, and patient
lymphoblasts prevents, to varying degrees, the mitochondrial dys-
function caused by the absence of TAZ and can additionally rescue
the sterility of male taz−/ − ﬂies (Malhotra et al., 2009a; Baile et al.,
2014b; Ye et al., 2014a). These results suggest that the mitochon-
drial dysfunction stemming from TAZ deﬁciency is not likely due
to reduced remodeled CL, but instead caused by the increased
abundance of MLCL and/or the low total amounts of CL. As
such, drugs that can scavenge mitochondrial ROS or prevent the
accumulation of MLCL (inhibit the activity of the upstreamdeacy-
lase(s); enhance the activity of other putative MLCL remodelers;
augment a pathway that degrades MLCL) could be used to the
potential therapeutic beneﬁt of BTHS patients.
DNAJC19 MUTATIONS LEADING TO DILATED CARDIOMYOPATHY WITH
ATAXIA (DCMA) SYNDROME
To date, only two mutations have been identiﬁed in DNAJC19
(DnaJ/Hsp40 homolog, subfamily C, member 19) that are asso-
ciated with dilated cardiomyopathy with ataxia (DCMA; Davey
et al., 2006; Ojala et al., 2012), an autosomal-recessive disorder that
presents with early onset dilated cardiomyopathy, non-progressive
cerebellar ataxia leading to motor delays, testicular dysgenesis,
growth failure, and elevated levels of 3-MGA. Additional features
include microcytic anemia, mild to borderline non-progressive
mental retardation, hepatic steatosis, and occasional optic atrophy
(Davey et al., 2006; Sparkes et al., 2007; Ojala et al., 2012). DCMA
shares with BTHS certain clinical features including left ventricu-
lar non-compaction with spongey and trabeculated myocardium
(Sparkes et al., 2007). However, unlike in BTHS (Barth et al., 2004),
DCMA patients do not exhibit neutropenia or skeletal myopathy.
DNAJC19 is on chromosome 3q26.33 (Davey et al., 2006). The
gene consists of six exons and is ubiquitously expressed as a 525 bp
transcript with a minor 435 bp form, lacking exon 4, in all tissues
tested and control ﬁbroblasts (Davey et al., 2006). The consan-
guineous Canadian Dariusleut Hutterite families all have an exon4
splicing defect while two Finnish brothers have a frameshift muta-
tion resulting in a truncated protein (Davey et al., 2006; Ojala
et al., 2012). Consistent with these mutations, only the shorter
transcript is expressed in ﬁbroblasts from one Hutterite patient
(Davey et al., 2006) andDNAJC19protein is not detected inﬁbrob-
lasts derived from the Finnish siblings (Ojala et al., 2012). Since
there are only two genetic variants of DNAJC19 linked to DCMA,
it is not possible to describe genotype–phenotype correlations in
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this disorder. Still, in a retrospective study of the Hutterite patients
that all share the same mutation (Sparkes et al., 2007), 13 of the
17 patients developed dilated cardiomyopathy and 10 later died.
Interestingly, three patients had resolved or stabilized cardiomy-
opathy and another four did not present with cardiac defects at
all. Thus, there is signiﬁcant clinical variability with respect to this
particular DCMA allele.
DNAJC19 is associated with the matrix-facing leaﬂet of
the IMM via a predicted NH2-terminal transmembrane region
(Richter-Dennerlein et al., 2014) and contains a conserved DNAJ
domain at the COOH terminus, in contrast to other conven-
tional DNAJ-proteins with an NH2-terminal J-domain. DNAJ
domain-containing proteins typically act as molecular chaperones
for Hsp70/Hsp40s and prevent protein aggregation by aiding in
the folding and assembly of newly synthesized proteins (Ohtsuka
and Hata, 2000; Mayer and Bukau, 2005). Sequence alignment
indicates that DNAJC19 is orthologous to yeast Pam18p, a con-
stituent of the TIM23 import machinery (Mokranjac et al., 2003).
In yeast, the Pam18p and Mdj2p proteins are essential compo-
nents of the TIM23 translocation machinery (Mokranjac et al.,
2005), interacting with mitochondrial Hsp70p, Pam16p, and
Tim44p to form the presequence translocase-associated motor
complex (Schneider et al., 1994; Moro et al., 2002; Truscott
et al., 2003; Frazier et al., 2004; Kozany et al., 2004; D’Silva
et al., 2008). This subcomplex associates with the core TIM23
translocon (consisting of Tim23p, Tim17p, Tim50p and vari-
ably, Tim21p) and mediates import of precursors destined for
the matrix in an ATP- and membrane potential-dependent man-
ner (Bomer et al., 1997; Moro et al., 1999; Geissler et al., 2002;
Yamamoto et al., 2002; Chacinska et al., 2005; van der Laan
et al., 2007). Thus, DNAJC19 may, like yeast Pam18p, stim-
ulate the ATPase activity of mtHsp70 and stabilize mtHsp70
binding to incoming peptides. For an excellent review on
mitochondrial protein translocation, refer to (Chacinska et al.,
2009).
Consistent with a role in protein import, DNAJC19 inter-
acts with MAGMAS, the conserved mammalian ortholog of
yeast Pam16p that is essential for development (Gonczy et al.,
2000; Jubinsky et al., 2001, 2003; D’Silva et al., 2005). MAGMAS
is structurally similar to DNAJC19 but peripherally associated
with the matrix-leaﬂet of the IMM. The interaction between
DNAJC19 and MAGMAS occurs via their reciprocal J-domains
and is required to recruit DNAJC19 to the core TIM23 translo-
con (Sinha et al., 2010). MAGMAS then associates with TIM17,
a subunit of the TIM23 core, to form the TIM23 translocation
machinery (Mehawej et al., 2014; Sinha et al., 2014). Interest-
ingly, there are three distinct forms of TIM23 translocon that
incorporate different TIM17 isoforms and associate with either
DNAJC15 (TIM17a; translocase A), another co-chaperone of
the same Hsp40-type (Hatle et al., 2013; Schusdziarra et al.,
2013), or DNAJC19 (TIM17b1 and TIM17b2; translocase Bs).
Of the three versions of TIM23, translocase Bs are critical
for basal mitochondrial biogenesis (e.g., OXPHOS, iron–sulfur
cluster biogenesis, mtDNA copy number, and maintenance of
mitochondrial membrane potential) while translocase A plays
a dispensable, albeit supportive role when translocase Bs are
absent (Sinha et al., 2014). In light of these results, defects in
mitochondrial presequence protein import and consequently,
mitochondrial biogenesis, may represent the mechanism of
DCMA pathogenesis.
Recently, however, human and murine DNAJC19 were
found to additionally interact with prohibitin (PHB complexes)
(Richter-Dennerlein et al., 2014). PHB complexes are large hetero-
oligomeric complexes composed of PHB1 and PHB2 subunits
(Tatsuta et al., 2005) that are involved in cristae morphogenesis
(Merkwirth et al., 2008) and modeled to function as lipid scaf-
folds in the IMM, redistributing lipids such as CL (Christie et al.,
2011) and delineating functional membrane domains (Osman
et al., 2009b). In yeast, phb1 is synthetically lethal with crd1
highlighting the importance of conserved PHB complexes in
CL metabolism (Osman et al., 2009a). Interestingly, DNAJC19-
depletion in HEK293T cells shifts the CL acyl proﬁle to longer
and less saturated chains; however, CL levels are unaffected and
MLCL does not accumulate (Richter-Dennerlein et al., 2014).
Moreover, while a functional DNAJ-domain is not required for
DNAJC19 to interact with PHB complexes, it is necessary to res-
cue the changes in CL molecular composition that occur upon
DNAJC19 knockdown (Richter-Dennerlein et al., 2014). In con-
trast, PHB2 knockdown results in the same three biochemical
alterations that characterize BTHS (increased MLCL, decreased
CL, and changes in CL acyl chain composition), although the
increase in MLCL is signiﬁcantly less than in TAZ knockdown
cells (Richter-Dennerlein et al., 2014). Concomitant knockdown
of PHB2 or DNAJC19 with TAZ does not alter the accumulation
of MLCL that occurs upon depletion of TAZ alone, indicating
that neither PHB complexes nor DNAJC19 are required to gen-
erate the substrate, MLCL, used by TAZ. Combined, these results
suggest unexpected roles for both PHB complexes and DNAJC19
in CL remodeling and further indicate that their functions in
this regard, are at least partially distinct. TAZ does not inter-
act with PHB2 or DNAJC19 directly (Richter-Dennerlein et al.,
2014). Thus, the ability of PHB/DNAJC19 complexes to deﬁne
speciﬁc membrane domains, such as those with negative curva-
ture, is postulated to confer acyl chain speciﬁcity to TAZ (Schlame
et al., 2012a; Richter-Dennerlein et al., 2014). In the absence of
such privileged domains, TAZ remodeling still occurs, it just lacks
acyl chain speciﬁcity.
In sum, it appears that DNAJC19 has dual functions in the reg-
ulation of CL remodeling and mitochondrial protein biogenesis
(Figure 5). A key question that remains unresolved iswhether both
activities contribute to DCMA disease pathogenesis. Presently
lacking is any information regarding the lipid proﬁle and protein
import functionality of mitochondria isolated from actual DCMA
patients; such data is needed to better understand the underlying
pathogenic mechanism. If similar alterations in CL are detected in
DCMA patient cells, future studies will be needed to deﬁne how
DNAJC19/PHB complexes regulate the collection of acyl chains
attached to CL and relate these changes to mitochondrial dysfunc-
tion. This latter question is all the more interesting and relevant
given that in yeast, ﬂies, and mammalian cells, genetically and/or
pharmacologically preventing production of MLCL by targeting
the lipase that begins the remodeling cascade rescues the multi-
tude of phenotypes attributed to TAZ deﬁciency (Malhotra et al.,
2009a; Baile et al., 2014b; Ye et al., 2014a).
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FIGURE 5 | Potential mechanisms of DCMA mitochondrial dysfunction.
(A) Under physiological conditions, DNAJC19 is targeted to TIM17B by
MAGMAS and associates with components of the TIM23 translocation
machinery, forming translocase B. DNAJC19 is homologous to yeast
Pam18p which stimulates the mtHsp70 activity of the PAM
(presequence-associated motor) complex and stabilizes binding of
incoming precursors. Moreover, DNAJC19 also interacts with prohibitin-2
(PHB) of the PHB complexes. PHB1/PHB2 oligomers form ring-like
complexes that are modeled to delineate specialized membrane domains.
Functional segregation of CL and TAZ in such domains may confer acyl
chain speciﬁcity to TAZ, allowing it to perform physiologically relevant CL
remodeling (green). Thus, DNAJC19 may participate in both mitochondrial
presequence protein import as well as formation of membrane domains
that are important for TAZ-based CL remodeling. (B) In the absence of
DNAJC19, the ability of the TIM23 machinery to import proteins across
the IMM may be compromised. Consequently, the biogenesis of
mitochondrial proteins, such as subunits of respiratory complexes, may be
reduced. (C) Further, loss of DNAJC19 prevents the PHB complex-based
generation of privileged membrane domains. In the absence of such
domains, TAZ remodeling, which may still occur, lacks speciﬁcity (red). For
clarity, not all components of the TOM, TIM, and PAM complexes are
depicted.
SERAC1 MUTATIONS LEADING TO MEGDEL SYNDROME
Evidence that PG, like CL, undergoes physiologically important
remodeling was recently provided by the identiﬁcation of serine
active site containing 1 (SERAC1) mutations that cause autosomal-
recessive MEGDEL syndrome [3-MGA, sensorineural deafness,
encephalopathy, and neuroradiological evidence of progressive
Leigh-like syndrome (Wortmann et al., 2006, 2012)]. In addition
to classical MEGDEL symptoms, an increasing list of clinical
phenotypes have been associated with SERAC1 mutations; infan-
tile mitochondrial hepatopathy, psychomotor and developmental
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delay, bilateral optic nerve atrophy, myoclonic epilepsy, and
microcephaly (Sarig et al., 2013; Lumish et al., 2014; Vilarinho
et al., 2014; Wedatilake et al., 2014). Similar to BTHS and DCMA,
MEGDEL patients have 3-MGA and variable mitochondrial
dysfunction.
SERAC1 is located on chromosome 6q25.3 and the encoded
protein resides in the MAM (Wortmann et al., 2012). SERAC1 is
a predicted single-pass transmembrane protein that is 654 amino
acids long and translated from17 exons into three isoforms (Wort-
mann et al., 2012). Theprotein is amember of thePGAP (post-GPI
attachment to protein 1)-like protein domain family and con-
tains an α/β-hydrolase fold and a highly conserved serine-lipase
domain (Wortmann et al., 2012). To date, 18 different mutations
have been described in 24 patients, many of which are frameshift,
nonsense, or missense mutations within or upstream of the lipase
domain (Karkucinska-Wieckowska et al., 2011; Wortmann et al.,
2012; Sarig et al., 2013; Tort et al., 2013; Dweikat et al., 2014;
Lumish et al., 2014; Vilarinho et al., 2014; Wedatilake et al., 2014).
Of note, a patient recently described with severe, early onset
MEGDEL symptoms harbors compound frameshift and stop-gain
heterozygous mutations upstream of the lipase domain (Lumish
et al., 2014). In contrast to patients with variants within the lipase
domain, which may allow for a protein with residual activity, the
production of truncated SERAC1 completely lacking the lipase
domain from both alleles may account for the severity of the
particular patient’s phenotype.
SERAC1 is implicated in changing the acyl chain composition
of CL’s precursor, PG. Speciﬁcally, MEGDEL patient ﬁbroblasts
have elevated concentrations of PG-34:1 and lower concentra-
tions of PG-36:1; the acyl chain compositions of the other
major phospholipid classes, with the notable exception of CL,
are normal (Wortmann et al., 2012). The inability to convert
PG-34:1 to PG-36:1 results in the accumulation of PG-34:1 and
subsequent incorporation of PG with these acyl chain species
into CL. Thus, in MEGDEL patients, CL levels are normal but
the acyl chain composition of CL is altered (Wortmann et al.,
2012). As in the case of DNAJC19 deﬁciency, if and how nor-
mal levels of CL of abnormal acyl chain composition affects
mitochondrial function is at present unclear. Notably, most
MEGDEL patient tissues and ﬁbroblasts exhibit OXPHOS dys-
function (Wortmann et al., 2006, 2012; Karkucinska-Wieckowska
et al., 2011; Sarig et al., 2013; Tort et al., 2013; Dweikat et al., 2014;
Wedatilake et al., 2014), though the degree of impairment and the
affected respiratory chain component(s) varies. Moreover, ROS
production is increased and catalase levels decreased in ﬁbrob-
lasts derived from at least one MEGDEL patient (Karkucinska-
Wieckowska et al., 2011); therefore, similar to BTHS, defective
OXPHOS function may cause an imbalance in redox home-
ostasis in MEGDEL patients. However, additional basic work
is required to deﬁne whether increased ROS production and
reduced scavenging is a consistent feature associated with SERAC1
dysfunction, exactly how defective SERAC1 variably impairs
OXPHOS, and if the changes noted in the acyl chain composi-
tion of CL in MEGDEL patients are detrimental to mitochondrial
functionality.
It is curious to note that endogenous TAZ,which is presumably
functional in MEGDEL patients, is unable to correct the unusual
CL acyl chains that accumulate in the absence of SERAC1 function.
PG is a precursor of CL and therefore contributes directly to
the collection of acyl chains associated with pre-remodeled CL.
Since other phospholipids have normal acyl chain compositions in
MEGDEL patients (Wortmann et al., 2012), in theory, TAZ should
still be able to generate “normal” CL. One possible explanation
for this discrepancy is that perhaps the CL that accumulates in
MEGDEL patients is not a substrate for the lipase that functions
upstream of TAZ to initiate CL remodeling.
While SERAC1 defects do not affect the abundance or acyl
chain pattern of phosphatidylcholine, phosphatidylserine, or PE,
it does signiﬁcantly reduce levels of BMP (Wortmann et al., 2012),
a lipid implicated in endosomal/lysosomal homeostasis and func-
tion (Hullin-Matsuda et al., 2009; Figure 6). BMP levels regulate
cholesterol trafﬁcking with low intracellular BMP causing accu-
mulation of free cholesterol in late endosomes. Indeed, SERAC1
patient ﬁbroblasts accumulate unesteriﬁed cholesterol (Sarig et al.,
2013; Tort et al., 2013) and patient biopsies show dramatically
disorganized striated muscle ultrastructure with abnormal mito-
chondria and lysosomal accumulation of neutral fat droplets
(Wortmann et al., 2012; Wedatilake et al., 2014). It is presently
not clear how a change in the acyl chain composition of PG trans-
lates into lower amounts of BMP especially since the molecular
composition of BMP in MEGDEL patients is not altered relative
to controls (Wortmann et al., 2012). Also unclear is how PG pro-
duced on the matrix side of the IMM gains access to SERAC1,
which resides in the MAM. As our understanding of how SERAC1
regulates the acyl chain composition of CL and the production
of BMP is in its infancy, future basic work is needed to develop
assortedmodels designed to better understand these processes and
how their disturbance cause the numerous MEGDEL syndrome
phenotypes.
ACYLGLYCEROL KINASE MUTATIONS LEADING TO SENGERS
SYNDROME
Sengers syndrome is caused by the absence of the IMS-residing
AGK (Calvo et al., 2012; Mayr et al., 2012; Haghighi et al., 2014).
Symptoms of Sengers syndrome may present at birth, childhood,
or early adulthood and its clinical manifestations range from
being severe, causing death in infancy, to mild, allowing sur-
vival into adulthood (van Ekeren et al., 1993; Mayr et al., 2012).
This autosomal-recessive disorder is characterized by congenital
cataracts, hypertrophic cardiomyopathy, skeletal myopathy, exer-
cise intolerance, lactic acidosis, and increased urinary 3-MGA;
though motor development is delayed, mental development of the
affected individuals are normal (Sengers et al., 1975). Hence, the
phenotypic spectrum associated with Sengers syndrome substan-
tially overlaps with both Barth and DCMA syndromes. Sengers
syndrome was originally thought to be due to deﬁciencies in the
level and/or function of adenine nucleotide translocase 1 (ANT1;
Jordens et al., 2002). ANT1 is the heart/muscle isoform of the
mitochondrial ADP/ATP exchanger that plays a fundamental role
inOXPHOSbymediating theﬂuxof ADPandATPacross the IMM
(Li et al., 1989). However, genetic analyses excluded mutations in
the ANT1 gene; as such, it was subsequently proposed that tran-
scriptional, translational, or post-translational events might be
responsible for the lower amounts of ANT1 observed in patients
www.frontiersin.org February 2015 | Volume 6 | Article 3 | 15
Lu and Claypool Mitochondrial phospholipid disorders
FIGURE 6 | Potential consequences of the absence of SERAC1
activity. (A) PG that is generated on the matrix-leaﬂet of the IMM is
trafﬁcked out of the mitochondrion and remodeled by SERAC1 on the
ER MAMs. Remodeled PG can subsequently serve as substrate for
BMP and CL synthesis. BMP in the endosomsal/lysosomal
compartments regulates (green arrow) cholesterol esteriﬁcation and
trafﬁcking out of the compartment. (B) In the absence of a functional
SERAC1, PG is not remodeled and accumulates shorter acyl chain
moieties. The decrease in acyl chain length somehow reduces overall
BMP levels, perhaps because the unremodeled PG is a poor precursor
for BMP synthesis. Reduced BMP levels in the endosome/lysosome
impairs cholesterol esteriﬁcation (inhibition in red) and leads to
decreased (red arrows) cholesterol efﬂux. The lack of SERAC1 also
changes the steady state composition of CL acyl chains. Blue arrows
denote enzymatic reactions and lipid movements. Dashed arrows
describe uncharacterized steps and pathways.
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(Jordens et al., 2002). Recently, two groups localized the defect via
exome sequencing, not in or around ANT1, but instead to the
AGK locus on chromosome 7q34 (Calvo et al., 2012; Mayr et al.,
2012).
The AGK gene contains 17 exons and encodes for a 422 amino
acid protein; it is a mitochondrial membrane-associated, multi-
substrate lipid kinase that contains domains that are highly homol-
ogous to sphingosine kinase-2 as well as DAG kinase (Topham
and Prescott, 1999; Waggoner et al., 2004; Bektas et al., 2005).
When phylogenetic analyses of AGK were undertaken, sequence
comparisons to other lipid kinases such as DAG, ceramide, and
sphingosine kinases revealed that despite containing a highly
conserved DAG kinase catalytic domain, human and murine
AGK segregate to a unique branch and are not members of any
previously described lipid kinase family (Waggoner et al., 2004).
Like Barth andDCMA syndromes, genotype–phenotype corre-
lations in Sengers syndrome are not readily apparent. For instance,
there are Sengers syndrome patients who are non-syndromic or
do not develop lactic acidosis (Aldahmesh et al., 2012), and sib-
lings who share the same mutation but present with very different
disease courses [one had the severe form of disease and died at
15 months of age while the other brother, at 3 years old, was
without skeletal myopathy or physical limitations (Siriwardena
et al., 2013)]. Thus, the etiology of Sengers syndrome is also likely
to involve genetic modiﬁers that can signiﬁcantly affect disease
progression and severity.
However, there is evidence that a genotype–phenotype corre-
lation for Sengers syndrome patients potentially exists (Haghighi
et al., 2014). Two forms of the syndrome have been described, a
severe neonatal form that leads to infantile death (Smeitink et al.,
1989) and a more benign, but chronic, form that has allowed
survival into the fourth decade (van Ekeren et al., 1993). The
former disease type is always associated with homozygous AGK
nonsense mutations while in the latter, patients usually harbor at
least one splice site variant or a start codon mutation, but not
doubly null/missense alleles (Haghighi et al., 2014). Presumably,
aberrant splicing of the COOH terminal exons (in or after the
DAG kinase domain) produces proteins with residual AGK activ-
ity while inactivation of the canonical start site allows for initiation
at an alternative/cryptic start site (Starck et al., 2012). In support
of this possible genotype–phenotype relation, the oldest surviving
patients (>35 years) carry either heterozygous start site and stop
codon mutations or a homozygous mutation affecting exon 15–16
splicing (Lalive D’Epinay et al., 1986; van Ekeren et al., 1993).
A role for AGK in the assembly, stability and/or regulation of
OXPHOS components such as ANT1 and complex I has been
speculated (Pitkanen et al., 1996; Haghighi et al., 2014). OXPHOS
defects in patient samples have been variable (Pitkanen et al.,
1996; Jordens et al., 2002; Morava et al., 2004; Aldahmesh et al.,
2012; Calvo et al., 2012; Mayr et al., 2012; Siriwardena et al., 2013;
Haghighi et al., 2014). In themore severe cases,ANT1 and complex
I levels are low and the mtDNA copy number reduced. However,
in the milder cases, OXPHOS function is spared. Curiously, ANT1
levels are normal in undifferentiated myoblasts but are dramati-
cally reduced upon myoblast differentiation (Mayr et al., 2012).
This observation is notable as it suggests that ANT1 stability
is compromised during muscle ﬁber differentiation in Sengers
syndrome patients. While the exact molecular function of AGK
is not known, its potential role in CL metabolism is consistent
with the varied bioenergetic impairments, structurally abnormal
mitochondria, and lipid and glycogen deposits in patient-derived
skeletal and cardiac muscle (Sengers et al., 1975; Siriwardena et al.,
2013). A comprehensive phospholipid analysis has not been per-
formed for Sengers syndrome cells and/or tissues. Therefore,
whether the absence of AGK function correlates with disturbances
in phospholipid metabolism has not yet been established. If AGK
generates PA that contributes substantially to TAMM41’s substrate
pool (Figure 1), then the absence of AGK function should sig-
niﬁcantly impact downstream PG and CL synthesis. Given the
aforementioned results concerning the relative stability of ANT1
in undifferentiated versus differentiated myoblasts, the choice of
cell/tissue to analyze is likely to be critically important in uncov-
ering if and how AGK participates in mitochondrial phospholipid
metabolism. Such information is anticipated to shed crucial light
onto Sengers syndrome disease pathogenesis.
PHOSPHATIDIC ACID-PREFERRING PHOSPHOLIPASE A1 MUTATIONS
LEADING TO HEREDITARY SPASTIC PARAPLEGIA
Mutations in the phospholipase A1 family members DDHD1
(Bouslam et al., 2005; Tesson et al., 2012; Liguori et al., 2014) and
DDHD2 (Schuurs-Hoeijmakers et al., 2012; Gonzalez et al., 2013;
Citterio et al., 2014; Doi et al., 2014; Magariello et al., 2014) have
recently been linked to autosomal-recessive forms of hereditary
spastic paraplegia (HSP). HSPs are an extremely heterogeneous
group of inherited neurological disorders that are classiﬁed by
patients who present with (complex HSP) or without (uncompli-
cated or pureHSP) neurological defects. PureHSP is characterized
by progressive spasticity and weakness of the lower limbs. In
complex HSP, spastic paraplegia is compounded with neurolog-
ical and systemic abnormalities such as dementia, intellectual
disability, ataxia, and neuropathy, amongst others [see (Fink,
2013) for comprehensive discussion of HSP and spastic paraplegia
variants]. Furthermore, there is varied disease onset, progres-
sion, and “functional plateaus” (a point at which there is very
little further disability) between the HSPs and as such, there is
very little genotype–phenotype correlation in this heterogeneous
disorder.
Hereditary spastic paraplegia has been linked to over 50 genetic
loci, covering all chromosomes, of which only 22 genes have
been identiﬁed so far (Finsterer et al., 2012; Fink, 2013). Two of
the identiﬁed disease-associated genes are DDHD1 and DDHD2
that encode protein products with PA-phospholipase A1 activity.
DDHD1 is localized to chromosome 14q21.1, contains 12 exons
(Tesson et al., 2012) and encodes for the 872 amino acid protein,
PA-PLA1. Initial characterization identiﬁed substantial PA-PLA1
activity in bovine brain and testis that corresponds to the two
tissues with the highest DDHD1 mRNA expression (Higgs and
Glomset, 1994; Higgs et al., 1998). In humans, these two tissues,
along with heart and skeletal muscle, additionally contain high
levels of DDHD2, a more ubiquitously expressed DDHD family
member (Nakajima et al., 2002; Morikawa et al., 2009; Sato et al.,
2010). DDHD2 is both cytosolic and membrane-associated (Sato
et al., 2010; Baba et al., 2013). Located on chromosome 8p11.23
and containing 18 exons, DDHD2 is expressed as two major
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mRNA transcripts that correspond to the full length 711 amino
acid protein and another that lacks the COOH terminal DDHD
phospholipase domain. When patient ddhd2 mutants were over-
expressed in and partially puriﬁed from HEK293T cells, PA-PLA1
activity was either low or absent compared to overexpressed wt
DDHD2 (Doi et al., 2014). Notably, depletion of PA-PLA1 activ-
ity (DDHD1 or DDHD2) in some, but not all cells, can cause
mitochondrial elongation (Schuurs-Hoeijmakers et al., 2012; Baba
et al., 2013, 2014), presumably due to unopposed fusion. Thus, one
might expect that the balance between ﬁssion and fusion may be
disturbed in some cells in patients with ddhd1 or ddhd2 mutations
with an overall shift toward too much fusion. As active ﬁssion
is a crucial process for clearance of damaged mitochondria by
mitophagy, unopposed fusion could drive the accumulation of
dysfunctional mitochondria (Twig et al., 2008). Consistent with
the possible accretion of sub-optimal mitochondria, respiration
andATP levels are decreased and cytosolic ROS increased in ddhd1
patient-derived lymphoblasts (Tesson et al., 2012). Unfortunately,
PA levels and mitochondrial morphology have not been docu-
mented in either ddhd1 or ddhd2 patient-derived cells (Tesson
et al., 2012) but there are no major changes in phospholipids in
ddhd2−/ − mouse brains (Inloes et al., 2014).
It is unclear whether or not depletion of DDHD1 or DDHD2
can directly affect mitochondrial dynamics by accumulating pro-
fusogenicPAon theOMM.Given their similar substrate speciﬁcity,
they may have redundant roles in this regard. Still, there might
be functional differences for these two PA phospholipases that
are dictated by their expression patterns and subcellular distribu-
tions. As such, future studies are needed to investigate the potential
causative link between dysregulation of PA metabolism on the
OMM with disease pathogenesis for these subtypes of HSP.
PERSPECTIVES
Phospholipids are not simply cellular barriers that delineate
cells and organelles thus allowing biochemical pathways to be
compartmentalized and cross-regulated. Although predominantly
synthesized in the ER, some phospholipids, such as PG and CL,
are exclusively made in the mitochondrion, while others, such
as PE, involve a pathway that begins in the ER but is completed
in the cell’s powerhouse. In mitochondria, phospholipids are
important for an impressive array of functions. Indeed, when
phospholipid levels, molecular species, or distribution within
the mitochondrion is affected, as is the case for the diseases
discussed herein, mitochondrial dysfunction ensues. BTHS was
the ﬁrst known inborn error of mitochondrial phospholipid
metabolism. Since the identiﬁcation of TAZ as the causative
gene for BTHS, exome sequencing and basic research have both
contributed to the recent addition of new diseases that impinge
upon mitochondrial lipid metabolism. We propose to classify
these disorders as a new category of mitochondrial disease that
speciﬁcally impacts phospholipid homeostasis. The clinical het-
erogeneity of patient phenotypes reﬂects the variety of functions
that phospholipids partake in and their fundamental importance
for mitochondrial physiology. Future work needs to focus on
developing appropriate models for these diseases. As exempli-
ﬁed by BTHS, the availability and in-depth characterization of
such models will contribute enormously to our understanding of
each disease process and identify potential therapeutic strategies.
Further, such basic work should help us better understand dis-
ease mechanisms and provide explanations for shared and distinct
phenotypes.
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